Literature DB >> 18591462

Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study.

Archana Singh-Manoux1, David Gimeno, Mika Kivimaki, Eric Brunner, Michael G Marmot.   

Abstract

OBJECTIVE: The purpose of this study was to examine the relationship between fasting serum lipids and short-term verbal memory in middle-aged adults. METHODS AND
RESULTS: Total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and memory were measured twice, at mean ages 55 and 61, in 3673 male and female participants of the Whitehall II study. Short-term verbal memory was assessed using a 20-word list. Logistic regression was used to model associations between ATP-III categories of lipids and memory deficit (recall of < or =4 words) and decline (decrease of > or =2 words). Analyses were adjusted for education, occupational position, coronary heart disease, stroke, hypertension, use of medication, diabetes, smoking, and alcohol consumption. Compared to high HDL-C (> or =60 mg/dL), low HDL-C (<40 mg/dL) was associated with greater odds of memory deficit at the first (OR=1.27; 95% confidence interval [CI]=0.91 to 1.77) and second wave of this study (OR=1.53; 95% CI=1.04 to 2.25) in fully adjusted analysis. Decrease in HDL-C over the 5-year follow-up period was associated with decline in memory in the adjusted analysis (OR=1.61; 95% CI=1.19 to 2.16); no interaction with APOE e4 status was present.
CONCLUSIONS: HDL-C levels are potentially modifiable, and our results suggest that low HDL-C is associated with poor memory and decline in memory in middle-aged adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591462      PMCID: PMC2581752          DOI: 10.1161/ATVBAHA.108.163998

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans.

Authors:  R M Evans; C L Emsley; S Gao; A Sahota; K S Hall; M R Farlow; H Hendrie
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

3.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.

Authors:  Miia Kivipelto; Tiia Ngandu; Tiina Laatikainen; Bengt Winblad; Hilkka Soininen; Jaakko Tuomilehto
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

4.  The metabolic syndrome and Alzheimer disease.

Authors:  George Razay; Anthea Vreugdenhil; Gordon Wilcock
Journal:  Arch Neurol       Date:  2007-01

5.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study.

Authors:  Robert Stewart; Lon R White; Qian-Li Xue; Lenore J Launer
Journal:  Arch Neurol       Date:  2007-01

6.  Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women.

Authors:  Pirjo Komulainen; Timo A Lakka; Miia Kivipelto; Maija Hassinen; Eeva-Liisa Helkala; Irja Haapala; Aulikki Nissinen; Rainer Rauramaa
Journal:  Dement Geriatr Cogn Disord       Date:  2006-10-27       Impact factor: 2.959

7.  High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study.

Authors:  R L Sacco; R T Benson; D E Kargman; B Boden-Albala; C Tuck; I F Lin; J F Cheng; M C Paik; S Shea; L Berglund
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

8.  Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study.

Authors:  A Solomon; I Kåreholt; T Ngandu; B Winblad; A Nissinen; J Tuomilehto; H Soininen; M Kivipelto
Journal:  Neurology       Date:  2007-03-06       Impact factor: 9.910

9.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

Authors:  D L Sparks; D J Connor; M N Sabbagh; R B Petersen; J Lopez; P Browne
Journal:  Acta Neurol Scand Suppl       Date:  2006

Review 10.  Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence.

Authors:  M Kivipelto; A Solomon
Journal:  Acta Neurol Scand Suppl       Date:  2006
View more
  46 in total

1.  HDL cholesterol and the risk of depression over 5 years.

Authors:  O P Almeida; B B Yeap; G J Hankey; J Golledge; L Flicker
Journal:  Mol Psychiatry       Date:  2013-09-03       Impact factor: 15.992

Review 2.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

3.  Current serum lipoprotein levels and FMRI response to working memory in midlife.

Authors:  Mitzi M Gonzales; Takashi Tarumi; Danielle E Eagan; Hirofumi Tanaka; Fedora O Biney; Andreana P Haley
Journal:  Dement Geriatr Cogn Disord       Date:  2011-04-13       Impact factor: 2.959

4.  Physical Activity Is Associated With Lower Odds of Cognitive Impairment in Women but Not Men Living With Human Immunodeficiency Virus Infection.

Authors:  Felicia C Chow; Akintomiwa Makanjuola; Kunling Wu; Baiba Berzins; Kwang-Youn A Kim; Adesola Ogunniyi; Ronald J Ellis; Kevin Robertson; Katherine Tassiopoulos; Babafemi O Taiwo
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

Review 5.  HDL and cognition in neurodegenerative disorders.

Authors:  David A Hottman; Dustin Chernick; Shaowu Cheng; Zhe Wang; Ling Li
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

6.  Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function.

Authors:  Joanna M Karasinska; Franz Rinninger; Dieter Lütjohann; Piers Ruddle; Sonia Franciosi; Janine K Kruit; Roshni R Singaraja; Veronica Hirsch-Reinshagen; Jianjia Fan; Liam R Brunham; Nagat Bissada; Rajasekhar Ramakrishnan; Cheryl L Wellington; John S Parks; Michael R Hayden
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

7.  The association of cognitive performance with mental health and physical functioning strengthens with age: the Whitehall II cohort study.

Authors:  M Jokela; A Singh-Manoux; J E Ferrie; D Gimeno; T N Akbaraly; M J Shipley; J Head; M Elovainio; M G Marmot; M Kivimäki
Journal:  Psychol Med       Date:  2009-09-01       Impact factor: 7.723

8.  Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier.

Authors:  Anil Paul Chirackal Manavalan; Alexandra Kober; Jari Metso; Ingrid Lang; Tatjana Becker; Karin Hasslitzer; Martina Zandl; Elham Fanaee-Danesh; Jyotsna Brijesh Pippal; Vinay Sachdev; Dagmar Kratky; Jasminka Stefulj; Matti Jauhiainen; Ute Panzenboeck
Journal:  J Biol Chem       Date:  2013-12-25       Impact factor: 5.157

9.  Cardiovascular Risk Factors Associated with Smaller Brain Volumes in Regions Identified as Early Predictors of Cognitive Decline.

Authors:  Rajiv N Srinivasa; Heidi C Rossetti; Mohit K Gupta; Roger N Rosenberg; Myron F Weiner; Ronald M Peshock; Roderick W McColl; Linda S Hynan; Richard T Lucarelli; Kevin S King
Journal:  Radiology       Date:  2015-07-28       Impact factor: 11.105

10.  Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease.

Authors:  Alessandra Pani; Antonella Mandas; Giacomo Diaz; Claudia Abete; Pier Luigi Cocco; Fabrizio Angius; Annalisa Brundu; Nico Muçaka; Maria Elena Pais; Antonio Saba; Luigi Barberini; Cristina Zaru; Manuela Palmas; Paolo F Putzu; Alessandra Mocali; Francesco Paoletti; Paolo La Colla; Sandra Dessì
Journal:  BMC Med       Date:  2009-11-02       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.